Impact of proning with and without inhaled pulmonary vasodilators and neuromuscular blocking agents in COVID acute respiratory distress syndrome

Table 1 Demographics and comorbidities, n (%)

Characteristic	All	Control	Prone position ventilation ± rescue therapy	P value
n	114	25	89	-
Age (years) (mean ± SD)	58.32 ± 13.44	62.48 ± 14.84	57.18 ± 12.89	0.081
Sex
Female	25 (21.55)	14 (56.0)	35 (38.46)	0.116
Male	91 (78.45)	11 (44.0)	56 (61.54)
Race
African American	73 (69.93)	19 (76.0)	54 (59.34)	0.208
White	6 (5.17)	0 (0.00)	6 (6.59)
Other	37 (31.9)	6 (24.0)	31 (34.07)
Ethnicity
Hispanic or Latino	30 (25.86)	2 (8.0)	28 (30.77)	0.021a
Non-Hispanic or Latino	86 (74.14)	23 (92.0)	63 (69.23)
Body mass index (median, interquartile range)	30.7 (27.5, 39.2)	28.3 (24.3, 33.0)	32.8 (28.4, 40.0)	0.012a
Comorbidities
Immune disorders	11 (9.48)	1 (4.0)	10 (10.99)	0.291
Kidney disease	13 (11.21)	1 (4.0)	12 (13.19)	0.197
Liver disease	17 (14.66)	4 (16.0)	13 (14.29)	0.830
Diabetes	72 (62.07)	15 (60.0)	57 (62.64)	0.830
Heart disease	70 (60.34)	14 (56.0)	56 (61.54)	0.616
Hypertension	78 (67.24)	16 (64.00)	62 (68.13)	0.697
Discharge status
Expired	59 (50.86)	12 (48.0)	47 (51.65)	0.722
Inpatient rehab	10 (8.77)	1 (4.0)	9 (9.89)
Acute Care Hospital	16 (14.0)	4 (16.0)	12 (13.19)
Skilled nursing facility, long-term acute care	5 (4.31)	1 (4.0)	4 (4.40)
Home	23 (19.82)	7 (28.0)	16 (17.58)
Other	3 (2.58)	0 (0.00)	3 (3.30)

^aStatistically significant value (P < 0.05).